scholarly journals New Antituberculosis Drug FS-1

2019 ◽  
Author(s):  
Rinat Islamov ◽  
Bahkytzhan Kerimzhanova ◽  
Alexander Ilin
Keyword(s):  
Antituberculosis Drug

Mycobacterial DNA Replication as a Target for Antituberculosis Drug Discovery

2017 ◽  
Vol 17 (19) ◽  
pp. 2129-2142 ◽  
Author(s):  
Renata Płocinska ◽  
Malgorzata Korycka-Machala ◽  
Przemyslaw Plocinski ◽  
Jaroslaw Dziadek
Keyword(s):  
Drug Resistance ◽  
Dna Replication ◽  
Drug Targets ◽  
Rapid Development ◽  
New Drugs ◽  
Drug Resistant ◽  
Antituberculosis Drug ◽  
Nucleotide Synthesis ◽  
Antituberculosis Therapy ◽  
Optimal Drug

Background: Mycobacterium tuberculosis (M. tuberculosis), the causative agent of tuberculosis, is a leading infectious disease organism, causing millions of deaths each year. This serious pathogen has been greatly spread worldwide and recent years have observed an increase in the number of multi-drug resistant and totally drug resistant M. tuberculosis strains (WHO report, 2014). The danger of tuberculosis becoming an incurable disease has emphasized the need for the discovery of a new generation of antimicrobial agents. The development of novel alternative medical strategies, new drugs and the search for optimal drug targets are top priority areas of tuberculosis research. Factors: Key characteristics of mycobacteria include: slow growth, the ability to transform into a metabolically silent - latent state, intrinsic drug resistance and the relatively rapid development of acquired drug resistance. These factors make finding an ideal antituberculosis drug enormously challenging, even if it is designed to treat drug sensitive tuberculosis strains. A vast majority of canonical antibiotics including antituberculosis agents target bacterial cell wall biosynthesis or DNA/RNA processing. Novel therapeutic approaches are being tested to target mycobacterial cell division, twocomponent regulatory factors, lipid synthesis and the transition between the latent and actively growing states. Discussion and Conclusion: This review discusses the choice of cellular targets for an antituberculosis therapy, describes putative drug targets evaluated in the recent literature and summarizes potential candidates under clinical and pre-clinical development. We focus on the key cellular process of DNA replication, as a prominent target for future antituberculosis therapy. We describe two main pathways: the biosynthesis of nucleic acids precursors – the nucleotides, and the synthesis of DNA molecules. We summarize data regarding replication associated proteins that are critical for nucleotide synthesis, initiation, unwinding and elongation of the DNA during the replication process. They are pivotal processes required for successful multiplication of the bacterial cells and hence they are extensively investigated for the development of antituberculosis drugs. Finally, we summarize the most potent inhibitors of DNA synthesis and provide an up to date report on their status in the clinical trials.

scholarly journals Draft Genome Sequences of 12 Mycolicibacterium smegmatis Strains Resistant to Imidazo[1,2-b][1,2,4,5]Tetrazines

2019 ◽  
Vol 8 (16) ◽  
Author(s):  
Aleksey A. Vatlin ◽  
Kirill V. Shur ◽  
Valery N. Danilenko ◽  
Dmitry A. Maslov
Keyword(s):  
Draft Genome ◽  
Transcriptional Repressor ◽  
Antituberculosis Drug ◽  
Genome Sequences ◽  
Content Type ◽  
Drug Candidates

Here, we report 12 draft genome sequences of mutant Mycolicibacterium smegmatis strains resistant to imidazo[1,2-b][1,2,4,5]tetrazines, which are antituberculosis drug candidates. We have identified 7 different mutations in the MSMEG_1380 gene, which encodes the AcrR/TetR_N transcriptional repressor, which may activate efflux-mediated resistance.

scholarly journals CYP2E1, GSTM1, and GSTT1 genetic polymorphisms and their associations with susceptibility to antituberculosis drug-induced liver injury in Thai tuberculosis patients

Heliyon ◽  
2021 ◽  
Vol 7 (4) ◽  
pp. e06852
Author(s):  
Noppadol Chanhom ◽  
Sukanya Wattanapokayakit ◽  
Nusara Satproedprai ◽  
Supharat Suvichapanich ◽  
Surakameth Mahasirimongkol ◽  
...  
Keyword(s):  
Liver Injury ◽  
Genetic Polymorphisms ◽  
Antituberculosis Drug ◽  
Drug Induced ◽  
Tuberculosis Patients ◽  
Drug Induced Liver Injury

scholarly journals N′-Cyclododecylidenepyridine-4-carbohydrazide

2012 ◽  
Vol 68 (4) ◽  
pp. o1205-o1205
Author(s):  
Andreas Lemmerer ◽  
Joel Bernstein ◽  
Volker Kahlenberg
Keyword(s):  
Crystal Structure ◽  
Hydrogen Bonds ◽  
Functional Groups ◽  
Title Compound ◽  
Antituberculosis Drug ◽  
Compound C

The title compound, C18H27N3O, is a derivative of the antituberculosis drug isoniazid (systematic name: pyridine-4-carbohydrazidei). The crystal structure consists of repeatingC(4) chains along thebaxis, formed by N—H...O hydrogen bonds with adjacent amide functional groups that are related by ab-glide plane. The cyclododecyl ring has the same approximately `square' conformation, as seen in the parent hydrocarbon cyclododecane.

Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India

2013 ◽  
Vol 28 (8) ◽  
pp. 1368-1374 ◽  
Author(s):  
Vinod H Gupta ◽  
Deepak N Amarapurkar ◽  
Meenakshi Singh ◽  
Preetha Sasi ◽  
Jyotsna M Joshi ◽  
...  
Keyword(s):  
Cytochrome P450 ◽  
Gene Polymorphisms ◽  
Western India ◽  
Antituberculosis Drug ◽  
Cytochrome P450 2E1 ◽  
Drug Induced

Novel and revisited approaches in antituberculosis drug discovery

2017 ◽  
Vol 48 ◽  
pp. 94-101 ◽  
Author(s):  
Jennifer Herrmann ◽  
Jan Rybniker ◽  
Rolf Müller
Keyword(s):  
Drug Discovery ◽  
Antituberculosis Drug

Biodegradation of the Antituberculosis Drug Isoniazid in the Aquatic Environment

2014 ◽  
Vol 43 (2) ◽  
pp. 166-172 ◽  
Author(s):  
Samuel Sasu ◽  
Jörg Metzger ◽  
Martin Kranert ◽  
Klaus Kümmerer
Keyword(s):  
Aquatic Environment ◽  
Antituberculosis Drug

scholarly journals Outcomes of TB/HIV co-infected patients presenting with antituberculosis drug-induced liver injury

2015 ◽  
Vol 105 (5) ◽  
pp. 393 ◽  
Author(s):  
S Naidoo ◽  
D Evans ◽  
E Jong ◽  
K Mellet ◽  
R Berhanu
Keyword(s):  
Liver Injury ◽  
Antituberculosis Drug ◽  
Drug Induced ◽  
Drug Induced Liver Injury
Sign in / Sign up

Export Citation Format

Share Document